Suppr超能文献

RNF180/RhoC途径增强了由FZD7抑制介导的BCL6在胃癌中的恶性抑制和铁死亡促进作用。

The malignancy suppression and ferroptosis facilitation of BCL6 in gastric cancer mediated by FZD7 repression are strengthened by RNF180/RhoC pathway.

作者信息

Guo Shiwei, Deng Jingyu, Wang Pengliang, Kou Fan, Wu Zizhen, Zhang Nannan, Zhao Zhenzhen, Nie Yongzhan, Yang Lili

机构信息

Department of Immunology, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.

Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.

出版信息

Cell Biosci. 2023 Apr 14;13(1):73. doi: 10.1186/s13578-023-01020-8.

Abstract

BACKGROUND

B-cell lymphoma 6 (BCL6) is a transcription repressor that plays a tumor suppressor or promoting role in various tumors. However, its function and molecular mechanism in gastric cancer (GC) remain unclear. Ferroptosis, a novel programmed cell death, is closely related to tumor development. In this research, we aimed to explore the role and mechanism of BCL6 in malignant progression and ferroptosis of gastric cancer.

METHODS

Firstly, BCL6 was identified as an important biomarker that attenuated the proliferation and metastasis of GC through tumor microarrays and confirmed in GC cell lines. RNA sequence was performed to explore the downstream genes of BCL6. The underlying mechanisms were further investigated by ChIP, dual luciferase reporter assays and rescue experiments. Cell death, lipid peroxidation, MDA and Fe level were detected to determine the effect of BCL6 on ferroptosis and the mechanism was revealed. CHX, MG132 treatment and rescue experiments were used to explore the upstream regulatory mechanism of BCL6.

RESULTS

Here we showed that BCL6 expression was significantly decreased in GC tissues, and patients with low BCL6 expression showed more malignant clinical features and poor prognosis. The upregulation of BCL6 may significantly inhibited the proliferation and metastasis of GC cells in vitro and in vivo. In addition, we found that BCL6 directly binds and transcriptionally represses Wnt receptor Frizzled 7 (FZD7) to inhibit the proliferation, metastasis of GC cells. We also found that BCL6 promoted lipid peroxidation, MDA and Fe level to facilitate ferroptosis of GC cells by FZD7/β-catenin/TP63/GPX4 pathway. Furthermore, the expression and function of BCL6 in GC were regulated by the ring finger protein 180 (RNF180)/ras homolog gene family member C (RhoC) pathway, which had been elucidated to be involved in significantly mediating the proliferation and metastasis of GC cells.

CONCLUSIONS

In summary, BCL6 should be considered a potential intermediate tumor suppressor to inhibit the malignant progression and induce ferroptosis, which might be a promising molecular biomarker for further mechanistic investigation of GC.

摘要

背景

B细胞淋巴瘤6(BCL6)是一种转录抑制因子,在多种肿瘤中发挥抑癌或促癌作用。然而,其在胃癌(GC)中的功能及分子机制仍不清楚。铁死亡是一种新型的程序性细胞死亡,与肿瘤发展密切相关。在本研究中,我们旨在探讨BCL6在胃癌恶性进展和铁死亡中的作用及机制。

方法

首先,通过肿瘤微阵列鉴定出BCL6是一种可减弱GC增殖和转移的重要生物标志物,并在GC细胞系中得到证实。进行RNA测序以探索BCL6的下游基因。通过染色质免疫沉淀、双荧光素酶报告基因检测和挽救实验进一步研究其潜在机制。检测细胞死亡、脂质过氧化、丙二醛(MDA)和铁水平,以确定BCL6对铁死亡的影响并揭示其机制。使用环己酰亚胺(CHX)、MG132处理和挽救实验来探索BCL6的上游调控机制。

结果

我们发现,GC组织中BCL6表达显著降低,BCL6低表达的患者表现出更具恶性的临床特征和较差的预后。BCL6的上调可在体外和体内显著抑制GC细胞的增殖和转移。此外,我们发现BCL6直接结合并转录抑制Wnt受体卷曲蛋白7(FZD7),以抑制GC细胞的增殖和转移。我们还发现,BCL6通过FZD7/β-连环蛋白/TP63/谷胱甘肽过氧化物酶4(GPX4)途径促进脂质过氧化、MDA和铁水平,从而促进GC细胞的铁死亡。此外,BCL6在GC中的表达和功能受环指蛋白180(RNF180)/Ras同源基因家族成员C(RhoC)途径调控,该途径已被阐明在显著介导GC细胞的增殖和转移中起作用。

结论

总之,BCL6应被视为一种潜在的中间抑癌因子,可抑制恶性进展并诱导铁死亡,这可能是用于GC进一步机制研究的有前景的分子生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/10105459/6fa1c92bd67e/13578_2023_1020_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验